Abstracts tagged "Lupus nephritis"

Abstract Number: 2842 • 2016 ACR/ARHP Annual Meeting
Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
William Fung¹, Jiandong Su² and Zahi Touma³, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) manifests with proteinuria and/or active urine sediment. Renal composite indices include proteinuria, urinary active sediment (RBCs, casts) and serum creatinine.…
Abstract Number: 746 • 2016 ACR/ARHP Annual Meeting
Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
Ruth J. Pepper¹, Venkat Reddy², Scott Henderson³ and Maria J. Leandro⁴, ¹UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³UCL Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patients with lupus nephritis (LN) achieve variable clinical response following Rituximab (RTX) based B-cell depletion therapy, with rituximab treatment aiming to decrease the use…
Abstract Number: 2852 • 2016 ACR/ARHP Annual Meeting
Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
Aymeric Couturier¹, Vincent Molinie², Charles Cartou³, Serge ARFI⁴, Violaine Emal-Aglae⁵, Katlyne Polomat⁶, Florence MOINET⁶, Georges JEAN BAPTISTE⁷ and Christophe Deligny⁸, ¹nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ²Pathology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ³nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ⁴University Hospital, CHU Fort de France, Fort de France, Martinique, ⁵Nephrology, Centre Hospitalier de Mangot-Vulcin, Le Lamentin, Martinique, ⁶Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: In African-descent patients, lupus nephritis (LN) lead to a worse outcome than in Caucasians. Long term data are rare in countries where black populations…
Abstract Number: 749 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
Richard Furie¹, Ana Malvar², Sandra V. Navarra³, Karen Smirnakis⁴, Jessica Kong⁴, Nathalie Franchimont⁴ and Fei Shih⁴, ¹Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ²Nephrology Division, Hospital Fernandez, Buenos Aires, Argentina, ³Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁴Biogen, Cambridge, MA
Background/Purpose: The addition of an anti-TWEAK monoclonal antibody to SOC LN therapy did not improve 52-week RR rates in proliferative LN despite observed pharmacodynamic effects.…
Abstract Number: 2855 • 2016 ACR/ARHP Annual Meeting
The Long-Term Clinical Outcomes of Lupus Nephritis
Julie Davidson¹, Qinggong Fu², Beulah Ji³, Sapna Rao⁴, David Roth⁵, Laurence S Magder⁶ and Michelle Petri⁷, ¹Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ²Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, ³Clinical Development, GlaxoSmithKline R&D, Uxbridge, United Kingdom, ⁴Real World Evidence, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵GSK, Philadelphia, PA, ⁶Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Clinical trials in lupus nephritis have often been designed to demonstrate renal response (or remission) following therapy based on categorical remission endpoints (often no…
Abstract Number: 1180 • 2016 ACR/ARHP Annual Meeting
Class V Lupus Nephritis Results in Significant Numbers of End Stage Renal Disease and Death in a Population-Based Registry
Jennifer Brandt¹, Cristina Drenkard², Jason Cobb³, Gaobin Bao⁴ and S. Sam Lim⁴, ¹Department of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Department of Nephrology, Emory University School of Medicine, Atlanta, GA, ⁴Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Although the diagnosis of pure class V lupus nephritis (LN) is generally thought to portend a favorable prognosis, outcomes on a population-level are not…
Abstract Number: 3104 • 2016 ACR/ARHP Annual Meeting
Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis
Michelle Lopes¹, Luciana Seguro¹, Maite Castro², Danielle Daffre³, Eduardo Ferreira Borba² and Eloisa Bonfa⁴, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ³São Paulo University, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: Treat to target strategies are becoming the best approach for several rheumatic disorders. Recently retrospective analyses of two important lupus trials have reported that…
Abstract Number: 1394 • 2016 ACR/ARHP Annual Meeting
A Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Jennifer C. Cooper¹, B. Anne Eberhard², Marilynn Punaro³, Stacy P. Ardoin⁴, Hermine I. Brunner⁵, Joyce Hsu⁶, Linda Wagner-Weiner⁷, Kelly Rouster-Stevens⁸, Laura E. Schanberg⁹, Marisa Klein-Gitelman¹⁰, Emily von Scheven¹¹ and CARRA Registry Investigators, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Cohen Children's Medical Center of New York, New Hyde Park, NY, ³Texas Scottish Rite Hospital for Children, Dallas, TX, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁹Pediatrics, Duke Medical Center, Durham, NC, ¹⁰Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset systemic lupus erythematous (cSLE) patients are at higher risk for renal disease than those with adult-onset disease. Mycophenolate mofetil (MMF) and intravenous…
Abstract Number: 1396 • 2016 ACR/ARHP Annual Meeting
Cognitive Function in Children with SLE Nephritis: A Cross-Sectional Comparison to Children with Other Glomerular Chronic Kidney Diseases
Andrea Knight^1,2,3, Matthew Matheson⁴, Susan Furth⁵, Brad Warady⁶, Stephen Hooper⁷ and Amy Kogon⁸, ¹Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁵Division of Nephrology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Division of Nephrology, Children's Mercy Hospital, Kansas City, MO, ⁷Department of Allied Health Sciences, University of North Carolina School of Medicine, Chapel Hill, NC, ⁸Division of Nephrology, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Children with lupus nephritis (LN) are at risk for cognitive impairment due to effects on the brain from systemic inflammation and from potential effects…
Abstract Number: 1835 • 2016 ACR/ARHP Annual Meeting
Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway
Ou Jin, Chengcheng Hou, Qiuxia Li, Xi Zhang, Qiujing Wei, Hongyue Huang, Mingli Qiu and Jieruo Gu, Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China
Background/Purpose: () - -the Immunohistochemistry was to observe the expression of NOD2 in renal biopsies eal-time uantitative olymerase hain eactionPCR was used to detect the level of…
Abstract Number: 2061 • 2016 ACR/ARHP Annual Meeting
Successful Treatment of Murine Lupus Nephritis with Helminths Related Tuftsin-Phosphorylcholine Compound and Its Effect on the Microbiota
Yehuda Shoenfeld¹, Tomer Bashi², Hadar Gershon³, Or Givol⁴, Alexander Volkov⁵, Iris Barshack⁵, Mati Fridkin⁶, Miri Blank² and Omry Koren⁷, ¹Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ²Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ³Sefat Medical School, Bar-Ilan University, Sefat, Israel, ⁴Zabludowicz Center for Autoimmune Diseases, Ramat Gan, Israel, ⁵Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ⁶Organic chemistry, Weizmann Institute for Sciences, Rehovot, Israel, ⁷Sefat medical school, Bar-Ilan university, Sefat, Israel
Background/Purpose: , In areas where helminths infections are common, autoimmune diseases are rare. Treatment with helminthes and their ova, improved clinical findings of inflammatory bowel…
Abstract Number: 2794 • 2016 ACR/ARHP Annual Meeting
Sustained Complete Remission in Lupus Nephritis
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The durability of renal remission might be a predictor of good long-term renal outcome and survival in patients with lupus nephritis (LN). We aimed…
Abstract Number: 2016 • 2015 ACR/ARHP Annual Meeting
Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging
Premasany Kanapathippillai, Sayed Esmaeil Dorraji and Kristin A Fenton, RNA and Molecular Pathology, UIT, The Artic University of Norway, Tromso, Norway
Background/Purpose: The formation of tertiary lymphoid structures (TLS) are known to occur during the development of several diseases, including systemic lupus erythematosus (SLE), but in…
Abstract Number: 2508 • 2015 ACR/ARHP Annual Meeting
Adherence to ACR Guidelines in the Management of Lupus Nephritis – a Quality Improvement Initiative
Erik Anderson¹, Matthew Abramson¹, Sanjay Godhwani², Yaqi Xue³, Jie Yang³ and Heidi Roppelt⁴, ¹Internal Medicine, Stony Brook Hospital, Stony Brook, NY, ²Medicine/Rheumatology, Stony Brook Medicine, Setauket, NY, ³Stony Brook University, Stony Brook, NY, ⁴Rheumatology, SUNY Stony Brook Unversity Hospital, East Setauket, NY
Background/Purpose: Lupus nephritis not only decreases survival, but also its costs are substantial, likely due in part to deficits in care (Carls et al.,…
Abstract Number: 2900 • 2015 ACR/ARHP Annual Meeting
Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis
Amy Sandford¹, Malvika Gulati², Ademola Oliatan³, Angela Pakozdi², Ravindra Rajakariar⁴, Andrea Cove-Smith⁴ and Dev Pyne², ¹Barts Health NHS trust, London, United Kingdom, ²Rheumatology, Barts Health NHS Trust, London, United Kingdom, ³Barts Health NHS Trust, London, United Kingdom, ⁴Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Recently phospholipase A2 receptor 1 (PLA2R1) has been found to be the antigenic target for primary membranous nephropathy (pMN) (1). Circulating anti-PLA2R1 autoantibody can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].